| 영문 | agonist | 한글 | 작용제, 작용근 |
|---|---|---|---|
| 설명 | 1. 수용체와 결합하여 최대의 약리작용을 발현하는 화학물질을 말한다. 수용체에 특이하게 친화성을 가지고 있다. 생체 안에서 생산되는 내인성인 것과 생체 밖에서 투여되는 외인성인 것이 있다. 부분 작용제는 수용체와 결합해도 100%의 약리작용을 발현하지는 않으며 용량을 증가시켜도 효과는 커지지 않는다. 2. 해부학에서는 주가 되어 움직이는 근육의 무리 |
||
| 영문 | histamine | 한글 | 히스타민 |
|---|---|---|---|
| 설명 | 히스타민이란 비만세포과 호염기구라는 세포에 많이 있는 물질로써 기능은 다음과 같다. 1. 모세혈관의 이완과 투과성의 증가 2. 내장에 분포하는 근육의 수축 3. 위산의 분비촉진 4. 심장박동수의 증가 히스타민이 분비되어 다른 세포에 영향을 주어 위와 같은 역할을 하려면 반드시 세포표면에 있는 히스타민 수용체와 결합을 하여야한다. 이 히스타민 수용체에는 두 가지가 있다. 하나는 H1-수용체라고 하는 것인데 이 수용체는 위의 작용중에서 1, 2번의 작용을 매개한다. 즉 H1-수용체에 히스타민이 부착할 때에 위의 1, 2번과 같은 작용이 일어난다. 다른 하나는 H2-수용체라고 하는 것인데 3, 4번의 작용을 매개한다. 그리고 안티히스타민도 각각 H1-수용체에 작용하는 것이 있고, H2-수용체에 작용하는 것이 있다. |
||
| IHSS(= HCMP) | Idiopathic Hypertrophic Subaortic Stenosis = Obstructive Idiopathic Hypertrophic Car... |
|---|---|
| ORA | opiate receptor agonist |
| PAA | partial agonist activity; phenylacetic acid; phosphonoacetic acid; physical abilities analysis; plas... |
| AHT | aggregation half time; antihyaluronidase titer; augmented histamine test; autogenous hamster tumor |
| H2 | blockers histamine blockers |
| R,S | receptor agonist |
|---|---|
| 8-OH-DPAT | 5-HT agonist 8-hydroxy-2-(di-n-propylamino) tetralin |
| 8-OH-DPAT | 5-HT(1A) receptor agonist, 8-hydroxy 2(di-n-propyl(amino)tetralin |
| (35)S | Agonist-stimulated |
| GNRH-a | GnRH agonist |
| histamine agonist | Drugs that bind to and activate histamine receptors. Although they have been suggested for a variety of clinical applications histamine agonists have so far been more widely used in research than therapeutically. (12 Dec 1998) |
|---|
| agonist | 1. <anatomy> A prime mover. 2. <pharmacology> A drug that has affinity for and stimulates physiologic activity at cell receptors normally stimulated by naturally occurring substances, thus triggering a biochemical response. (18 Nov 1997) |
|---|---|
| calcium channel agonist | <pharmacology> Agents that increase calcium influx into calcium channels of excitable tissues. This causes vasoconstriction in vascular smooth muscle and/or cardiac muscle cells as well as stimulation of insulin release from pancreatic islets. Therefore, tissue-selective calcium agonists have the potential to combat cardiac failure and endocrinological disorders. They have been used primarily in experimental studies in cell and tissue culture. (12 Dec 1998) |
| receptor agonist | A substance that mimics a specificneurotransmitter, is able to attach to that neurotransmitter's receptor and thereby produces the same action that theneurotransmitter usually produces. Drugs are often designed as receptor agonists to treat a variety of diseases and disorders whenthe original chemical substance is missing or depleted. (22 May 1997) |
| mixed opioid agonist-antagonist | <pharmacology> A compound that has an affinity for two or more types of opioid receptors and blocks opioid effects on one receptor type while producing opioid effects on a second receptor type. (13 Nov 1997) |
| muscarinic agonist | Drugs that bind to and activate muscarinic cholinergic receptors (receptors, muscarinic). Muscarinic agonists are most commonly used when it is desirable to increase smooth muscle tone, especially in the GI tract, urinary bladder and the eye. They may also be used to reduce heart rate. (12 Dec 1998) |
| opioid agonist | <pharmacology> Any morphine-like compound that produces bodily effects including pain relief, sedation, constipation and respiratory depression. (16 Dec 1997) |
| opioid partial agonist | <pharmacology> A compound that has an affinity for and stimulates physiologic activity at the same cell receptors as opioid agonists but that produces only a partial (i.e., submaximal) bodily response. (16 Dec 1997) |
| LH and RH agonist | <pharmacology> Particular medications that act as potent inhibitors of gonadotrophin (testosterone) secretion. They act to inhibit the production of testosterone through a feedback mechanism on the pituitary gland. LH and RH agonists are useful in the treatment of prostate cancer. (14 Oct 1997) |
| augmented histamine test | A test for maximal production of gastric acidity or anacidity; after preliminary administration of an antihistamine, histamine acid phosphate is injected subcutaneously in a dose of 0.04 mg/kg of body weight, followed by analysis of gastric contents. Synonym: augmented histamine test. (05 Mar 2000) |
| receptors, histamine | Cell-surface proteins that bind histamine and trigger intracellular changes influencing the behaviour of cells. Histamine receptors are widespread in the central nervous system and in peripheral tissues. Three types have been recognised and designated h1, h2, and h3. They differ in pharmacology, distribution, and mode of action. (12 Dec 1998) |
| receptors, histamine h1 | A class of histamine receptors discriminated by their pharmacology and mode of action. most histamine h1 receptors operate through the inositol phosphate/diacylglycerol second messenger system. Among the many responses mediated by these receptors are smooth muscle contraction, increased vascular permeability, hormone release, and cerebral glyconeogenesis. (12 Dec 1998) |
| receptors, histamine h2 | A class of histamine receptors discriminated by their pharmacology and mode of action. Histamine h2 receptors act via g-proteins to stimulate adenylate cylase. Among the many responses mediated by these receptors are gastric acid secretion, smooth muscle relaxation, inotropic and chronotropic effects on heart muscle, and inhibition of lymphocyte function. (12 Dec 1998) |
| receptors, histamine h3 | A class of histamine receptors discriminated by their pharmacology and mode of action. Histamine h3 receptors were first recognised as inhibitory autoreceptors on histamine-containing nerve terminals and have since been shown to regulate the release of several neurotransmitters in the central and peripheral nervous systems. (12 Dec 1998) |
| histamine | <biochemistry> Formed by decarboxylation of histidine. Potent pharmacological agent acting through receptors in smooth muscle and in secretory systems. Stored in mast cells and released by antigen. (See hypersensitivity). Responsible for the early symptoms of anaphylaxis. Also present in some venoms. (18 Nov 1997) |
| histamine agents | Drugs used for their actions on histaminergic systems. Included are drugs that act at histamine receptors, affect the life cycle of histamine, or affect the state of histaminergic cells. (12 Dec 1998) |
Synonyms : H1 Agonist, H1 Agonists, H2 Agonist, H2 Agonists, H3 Agonist, H3 Agonists, Histamine Agonist, Histamine H1 Agonist, Histamine H1 Receptor Agonist, Histamine H1 Receptor Agonists, Histamine H2 Agonist, Histamine H2 Receptor Agonist, Histamine H2 Receptor Agonists
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|